Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.

Atherosclerosis - 1 Feb 2026

Rosenson Robert S, Brinton Eliot A, Gaudet Daniel, Raal Frederick J, Baker-Smith Carissa, Moriarty Patrick M, Greber-Platzer Susanne, Bergeron Jean, McCrindle Brian W, Waldron Alpana, Ali Shazia, George Richard T, Pordy Robert, Zhao Xue-Qiao, Wiegman Albert

Abstract excerpt

BACKGROUND AND AIMS: Children and adolescents with homozygous familial hypercholesterolemia (HoFH) routinely require advanced lipid-lowering therapies (LLTs). We assess the long-term efficacy and safety of evinacumab, a novel LLT, in children and adolescents with HoFH. METHODS: Study 17100 (NCT04233918) was a phase 3, single-arm, open-label study enrolling 20 children aged 5-11 years with HoFH. ELIPSE-OLE...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Anticholesteremic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoprotein B-100

Share to Blood Component Removal

Share to Cholesterol, LDL

Share to Hyperlipoproteinemia Type II

Share to Proprotein Convertase 9

Share to Receptors, LDL

Source

Identifiers

PMID: 41505976
DOI: 10.1016/j.atherosclerosis.2025.120627

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.PMID 41505976Read ↗

Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.Semantic proximity Read ↗

Evolocumab in Pediatric Heterozygous Familial HypercholesterolemiaSemantic proximity Read ↗

Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.Semantic proximity Read ↗

Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary.Semantic proximity Read ↗

Evidence for improved survival with treatment of homozygous familial hypercholesterolemiaSemantic proximity Read ↗

Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study.Semantic proximity Read ↗

Successful pharmacological management of a child with compound heterozygous familial hypercholesterolemia and review of the recent literature.Semantic proximity Read ↗

Evinacumab for Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized TrialSemantic proximity Read ↗

Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry.Semantic proximity Read ↗

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.Semantic proximity Read ↗

Evolocumab in patients with homozygous familial hypercholesterolemia in India.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.